Colgate-Palmolive Company
CL
$83.72
+1.66%
Colgate-Palmolive Company is a global leader in the consumer defensive sector, operating primarily in the Household & Personal Products industry. Its core business encompasses oral care (Colgate), personal care (soaps, shower gels, deodorants), home care products, and specialty pet nutrition through its Hill's brand, with international sales constituting about 70% of its total business. The company is a dominant market player with a strong competitive identity built on powerful global brands, extensive distribution, and a significant presence in emerging markets. The current investor narrative revolves around its status as a classic defensive stock, with recent attention focused on its ability to navigate inflationary pressures, execute pricing strategies to protect margins, and deliver steady growth from its high-margin Pet Nutrition segment, even as it faces the challenge of a recent quarterly net income loss reported in Q4 2025.…
CL
Colgate-Palmolive Company
$83.72
Investment Opinion: Should I buy CL Today?
Rating & Thesis: Hold. CL is a high-quality defensive stock currently trading at a full valuation; investors should wait for a better entry point or clearer signs of sustained earnings recovery before committing new capital. This aligns with a mixed analyst consensus featuring both Buy and Hold ratings, reflecting the current debate.
Supporting Evidence: The primary valuation metric, the forward P/E of 20.96x, is reasonable but not compelling for a company with modest 5.78% revenue growth. The trailing P/E of 29.97x sits at a premium to the sector. Profitability is strong at the operating level (21.33% margin), but net income is volatile. The key supporting factor is the immense $3.63 billion in annual free cash flow, which funds a secure 2.85% dividend. The implied upside is ambiguous without explicit targets, but the stock trades midway between its 52-week high and low, suggesting a fair but not opportunistic price.
Risks & Conditions: The two biggest risks are valuation compression from its high trailing P/E and a failure to deliver on the earnings rebound priced into the forward multiple. This Hold rating would upgrade to a Buy if the stock price retreats to the $78-$82 range (compressing the forward P/E), or if the next two quarters conclusively demonstrate a return to consistent net profitability above $700 million quarterly. It would downgrade to a Sell if revenue growth decelerates below 4% or if leverage increases materially from current levels. The stock is currently fairly valued relative to its own history but carries a slight premium versus sector peers, implying the market expects a successful earnings normalization.
Sign up to view all
CL 12-Month Price Forecast
CL presents a classic 'GARP at a price' dilemma. Its defensive qualities, strong cash flow, and dominant market position are undeniable, but these are offset by a full valuation and recent earnings volatility. The base case of range-bound trading is most likely, as the company executes its steady playbook. The stance would upgrade to bullish on a pullback to the low $80s, which would improve the risk/reward profile significantly. Conversely, a breakdown below the 52-week low of $74.55 on failed earnings would trigger a bearish view. Monitoring the next quarter's net income is paramount to validate the forward P/E's assumption of normalized profits.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $108.84 and implied upside of +30.0% versus the current price.
Average Target
$108.84
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$67 - $109
Analyst target range
Analyst coverage for Colgate-Palmolive is robust, with data indicating activity from multiple major firms. The consensus sentiment leans bullish, as evidenced by recent institutional ratings which include several 'Buy' or 'Overweight' recommendations from firms like Citigroup, JP Morgan, B of A Securities, and Deutsche Bank (which upgraded from Hold to Buy in March 2026), alongside 'Hold' or 'Equal Weight' ratings from others like Barclays and Wells Fargo. The average analyst revenue estimate for the coming period is $24.06 billion, with an average EPS estimate of $4.88, providing a basis for forward valuation. The target price range, while not explicitly provided in the data, would be derived from these estimates and the observed forward P/E. The wide dispersion in analyst actions—from upgrades to maintains—and the mix of bullish and neutral ratings signals a degree of uncertainty or debate, likely centered on the sustainability of margin recovery, the impact of input cost inflation, and the growth trajectory of the Pet Nutrition segment. A tight target spread would indicate strong conviction, while a wider spread suggests differing views on these key drivers. The recent upgrade by Deutsche Bank is a positive signal that may reflect improving confidence in the company's near-term outlook following its Q4 report.
Bulls vs Bears: CL Investment Factors
The evidence presents a balanced but cautiously optimistic picture. The bull case is anchored in CL's defensive cash flows, strong underlying margins, and the market's expectation of an earnings recovery, as priced into the lower forward P/E. The bear case highlights valuation concerns, earnings volatility, and high leverage. Currently, the bull side holds a slight edge due to the company's fundamental resilience and the high probability that the Q4 loss was an anomaly. The single most important tension in the investment debate is whether CL's current premium valuation (29.97x trailing P/E) is justified by a return to sustained, high-quality earnings growth above 5-6%, or if it represents an overextended multiple vulnerable to compression if growth merely stabilizes.
Bullish
- Robust Free Cash Flow Generation: The company generated $3.63 billion in trailing twelve-month free cash flow, providing a strong foundation for its 2.85% dividend yield and share repurchases. This cash generation supports a high payout ratio of 85.5% and demonstrates the defensive, cash-generative nature of the business.
- Strong Underlying Operating Margins: Despite a Q4 net loss, the core business remains profitable with a quarterly operating margin of 21.33% and a gross margin of 60.15%. These healthy margins indicate pricing power and operational efficiency, with the net loss attributed to a one-time $970 million 'other expenses' item.
- Defensive Low-Beta Profile: With a beta of 0.331, CL is approximately 67% less volatile than the broader market. This characteristic makes it a classic defensive holding, likely to outperform during market downturns, as evidenced by its 6.31% YTD outperformance versus the SPY.
- Analyst Confidence in Earnings Recovery: The forward P/E of 20.96x is significantly lower than the trailing P/E of 29.97x, reflecting analyst consensus for a sharp earnings rebound to an estimated $4.88 EPS. Recent upgrades, including Deutsche Bank's move to Buy in March 2026, signal improving sentiment.
Bearish
- Elevated Valuation at Peak Historical P/E: The trailing P/E of 29.97x is above typical sector averages (low-to-mid 20s) and at the high end of CL's own recent historical range. This premium valuation leaves limited room for multiple expansion and increases sensitivity to earnings misses.
- Significant Quarterly Net Income Loss: Q4 2025 reported a net loss of $37 million, a stark reversal from Q3's $735 million profit. While likely non-operational, this volatility raises questions about earnings quality and predictability, dragging the TTM net margin down to 10.46%.
- High Financial Leverage: The debt-to-equity ratio stands at 147.93%, indicating a highly leveraged balance sheet. While supported by strong cash flow, this leverage increases financial risk in a rising interest rate environment and could constrain strategic flexibility.
- Persistent Relative Underperformance: The stock is down 10.15% over the past year, underperforming the SPY by 45 percentage points. Recent 1-month performance is -1.95% versus SPY's +7.36%, indicating a lack of momentum and investor rotation away from defensive names.
CL Technical Analysis
The stock is currently in a state of consolidation following a significant rally and subsequent pullback. Over the past year, the stock has declined by 10.15%, yet it has gained 8.46% over the last six months, indicating a recent recovery phase. With a current price of $85.81, it is trading approximately 45% above its 52-week low of $74.55 but still 14% below its 52-week high of $99.33, positioning it in the middle of its annual range, which suggests a balance between recovering momentum and lingering overhead resistance. Recent momentum shows a short-term divergence; the stock is down 1.95% over the past month, contrasting with a positive 1.53% gain over the last three months. This 1-month underperformance, especially against a strong market (SPY up 7.36% over the same period), signals a period of relative weakness and consolidation after the sharp run-up from January through February 2026. Key technical levels are clearly defined by the 52-week high of $99.33 as major resistance and the 52-week low of $74.55 as critical support. A breakout above resistance would signal a resumption of the prior uptrend, while a breakdown below support would indicate a failure of the recent recovery. The stock's beta of 0.331 indicates it is approximately 67% less volatile than the broader market (SPY), a characteristic of a classic defensive name that should exhibit lower volatility during market turbulence.
Beta
0.33
0.33x market volatility
Max Drawdown
-21.9%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
-10.8%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | -1.0% | +8.5% |
| 3m | -3.4% | +2.8% |
| 6m | +7.3% | +4.6% |
| 1y | -10.8% | +32.3% |
| ytd | +7.8% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue growth has been modest but positive, with the most recent quarterly revenue of $5.23 billion representing a 5.78% year-over-year increase. However, examining the quarterly sequence from Q1 2025 ($4.91B) to Q4 2025 ($5.23B) shows a steady upward trajectory in absolute revenue, though growth rates have moderated from the high-single digits seen earlier in the year. The business is segmented, with Oral, Personal and Home Care generating $4.03 billion and the higher-growth Pet Nutrition segment contributing $1.20 billion in the latest period. Profitability presents a mixed picture; the company reported a net loss of $37 million in Q4 2025, a significant deviation from the profitability of prior quarters (e.g., Q3 2025 net income of $735 million). This quarterly loss has dragged the trailing twelve-month net margin down to 10.46%. Gross margin remains robust at 60.15% for the quarter, and the operating margin was a healthy 21.33%, indicating the core business is sound, with the net loss likely attributable to significant one-time or non-operating items, such as the $970 million in 'total other income expenses net' reported in the Q4 income statement. The balance sheet and cash flow position is strong, underpinned by substantial free cash flow generation. The company's trailing twelve-month free cash flow is $3.63 billion, providing ample internal funding for dividends, share buybacks, and growth initiatives. However, the debt-to-equity ratio is elevated at 147.93%, indicating a leveraged capital structure, though this is common for mature, cash-generative firms in the sector. The current ratio of 0.995 suggests adequate, though not excessive, short-term liquidity.
Quarterly Revenue
$5.2B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Given the company's positive net income on a trailing basis, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio stands at 29.97x, while the forward P/E is notably lower at 20.96x. This significant gap implies the market expects a substantial recovery in earnings growth, aligning with the consensus EPS estimate of $4.88 for the coming period, following the anomalous Q4 loss. Compared to sector averages, Colgate's valuation presents a nuanced picture. Its trailing P/E of 29.97x is above typical defensive consumer staples averages (often in the low-to-mid 20s), suggesting a premium. This premium is likely justified by its strong global brand equity, consistent free cash flow generation, and the defensive nature of its business, which commands a stability premium, especially in uncertain economic environments. Historically, the stock's own valuation has been volatile, with the P/E ratio swinging dramatically in recent quarters due to earnings fluctuations, as seen in historical data where the Q4 2025 P/E was negative. The current trailing P/E of 29.97x is above the levels seen in much of 2023 and 2024 (often in the 20-28x range), indicating the stock is trading at the higher end of its recent historical valuation band. This suggests the market is pricing in a return to normalized, profitable earnings and may have limited room for multiple expansion unless growth accelerates meaningfully.
PE
30.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -430x~3280x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Colgate-Palmolive's primary financial risk stems from its elevated debt load, with a debt-to-equity ratio of 147.93%. While serviceable by its $3.63 billion TTM free cash flow, this leverage amplifies vulnerability to rising interest costs. Earnings volatility is a significant concern, as demonstrated by the swing from a $735 million profit in Q3 2025 to a $37 million loss in Q4, largely due to a $970 million non-operating expense. This erratic profitability, compressing the net margin to 10.46%, challenges the stock's premium valuation narrative. Furthermore, the current ratio of 0.995 indicates limited short-term liquidity, which could pressure operations if working capital needs spike unexpectedly.
Market & Competitive Risks: The stock's premium trailing P/E of 29.97x, above sector norms, creates substantial valuation compression risk if earnings growth fails to re-accelerate or if investor sentiment rotates away from defensive staples. Recent news highlights a 'rotation trade' from leaders to laggards, which could disadvantage stable names like CL if the market chases higher beta opportunities. Its low beta of 0.331, while defensive, also means it may lag during strong bull markets, as seen in its severe 1-year underperformance versus the SPY. Competitive risks are evergreen in its core categories, but the high-margin Pet Nutrition segment faces intense competition from both specialized and mass-market players.
Worst-Case Scenario: The most damaging scenario would involve a failure of the expected earnings recovery, coupled with a broader market sell-off that removes the defensive premium. If Q1 2026 results show continued pressure from the Q4 non-operating items or reveal underlying margin erosion, analyst estimates would be cut, triggering multiple compression. A re-rating towards its 52-week low of $74.55, driven by loss of confidence in the growth story, would imply a downside of approximately -13% from the current price of $85.81. Incorporating the stock's historical max drawdown of -21.9%, a realistic adverse scenario could see losses in the -15% to -20% range.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: The high trailing P/E of 29.97x could compress if earnings growth disappoints, leading to multiple contraction. 2) Financial Risk: An elevated debt-to-equity ratio of 147.93% increases vulnerability to rising interest rates. 3) Earnings Quality Risk: The volatile swing to a Q4 net loss of $37 million raises concerns about the predictability of bottom-line profits, despite strong operating margins. 4) Market Risk: As a low-beta (0.331) stock, CL may significantly underperform in strong bull markets, as evidenced by its 45-percentage-point underperformance vs. the SPY over the past year.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $88 and $95, as it delivers on consensus EPS of $4.88 and maintains its current valuation. The Bull Case (25% probability) could drive the stock to $99-$105 on multiple expansion and faster growth. The Bear Case (15% probability) would see a retest of support near $74-$82 if earnings falter. The most likely outcome is the Base Case, predicated on the assumption that the Q4 2025 net loss was a one-time event and profitability normalizes as analysts expect.
CL is fairly valued to slightly overvalued based on current metrics. Its trailing P/E of 29.97x is at a premium to both the sector average and its own historical range, suggesting the market is paying for stability and expecting an earnings recovery. The more relevant forward P/E of 20.96x is reasonable and implies the market expects EPS to rebound to $4.88. This valuation indicates the market is pricing in a successful return to normalized profitability, leaving little room for error. If growth remains in the mid-single digits, the stock is fairly priced; if it accelerates, it could be undervalued, but if it disappoints, the current multiple is vulnerable.
CL is a good buy for income-oriented, risk-averse investors seeking defensive exposure and a reliable 2.85% dividend yield supported by strong cash flow. However, for growth-oriented investors or those seeking maximum capital appreciation, it is less compelling due to its premium trailing P/E of 29.97x, modest revenue growth near 6%, and significant underperformance versus the market over the past year. The current price offers a fair, but not exceptional, entry point; a more attractive opportunity would arise on a pullback towards the low $80s, which would improve the margin of safety.
CL is unequivocally suited for long-term investment. Its value proposition is built on compounding dividends, brand durability, and defensive characteristics that play out over years, not quarters. The stock's low beta of 0.331 makes it a poor candidate for short-term trading, as it typically lacks the volatility for significant momentum moves. Given the current valuation at the higher end of its range, a long-term horizon (3-5 years minimum) allows investors to collect the dividend and benefit from the company's steady cash generation, while weathering potential short-term multiple compression. Short-term traders would find better opportunities elsewhere.